Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhangyanming Pian is a traditional Chinese medicine (TCM) formulated as tablets, primarily indicated for the treatment of early and middle-stage senile cataracts. It is classified as a non-prescription Chinese patent medicine. The drug's therapeutic actions, rooted in TCM principles, include tonifying the liver and kidney, clearing liver and brightening eyes, dispelling nebula, promoting blood circulation, removing blood stasis, moistening intestines, and promoting bowel movement. Its complex composition consists of numerous herbal ingredients, which collectively aim to alleviate symptoms associated with liver and kidney deficiency, such as dry eyes, monocular diplopia, and blurred vision. Recent research also explores its potential in conditions like diabetic retinopathy, dry eye syndrome, and retinitis pigmentosa, suggesting broader ophthalmic applications beyond its traditional use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhangyanming Pian.